CFSAN funding
This article was originally published in The Tan Sheet
Executive Summary
The Senate Appropriations Committee recommends that FDA's Center for Food Safety & Applied Nutrition receive $5.3 mil. in funding for its Adverse Event Report System in fiscal year 2007 - a figure that is $1 mil. higher than the President's budget request, according to a committee report released June 22. The proposed increase may be related to the June 21 introduction of legislation that would make serious adverse event reporting mandatory for dietary supplement firms. The committee "has recommended funding to continue enforcement of the provisions contained in DSHEA," the report adds. "It is the Committee's intent that these funds be prioritized by the agency to step up activities against products that are clearly in violation of DSHEA." The senators also are "concerned" that dietary supplement good manufacturing practices have not yet been released by FDA and "direct" the agency to issue them. The Agriculture Appropriations bill now heads to the full Senate after being passed by the committee...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.